{"filings":[{"id":527039,"accession_number":"0001193125-26-230774","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2026-05-19T20:13:42+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q1 revenue $11.8M (-1% YoY); net loss narrows to $0.5M; Cyclo G6 up 14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.8M, down 1% YoY; Cyclo G6 product revenue $3.6M (+14% YoY) on 15,500 probes sold.","Net loss $0.5M ($0.03/sh) compared to $1.7M ($0.10/sh) in Q1 2025; Non-GAAP adjusted EBITDA $0.3M.","Gross margin 40% vs 43% a year ago, pressured by tariffs and transition to low-cost manufacturers.","Cash $4.6M; company expects positive cash flow for full year 2026 despite typical Q1 usage.","FY2026 revenue guidance reaffirmed at $51M-$53M; adjusted opex guided $19M-$19.5M."],"consensus_eps_estimate":-0.0714,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":11799000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100163,"accession_number":"0001193125-26-126323","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q4 revenue $14.7M up 16% YoY; first positive adjusted EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $14.7M (+16% YoY); retina $8.9M (+22%), Cyclo G6 $3.8M (+15%).","Q4 net loss improved to $0.2M ($0.01 EPS) from $0.8M ($0.05 EPS) in Q4 2024.","FY 2025 revenue $52.7M (+8% YoY); net loss $4.4M ($0.26) vs $8.9M ($0.54) in 2024.","First positive adjusted EBITDA of $1.1M in FY 2025 (vs -$4.3M in 2024) and Q4 $0.8M.","FY 2026 guidance: revenue $51M-$53M; positive operating cash flow; OpEx $19M-$19.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100162,"accession_number":"0001193125-26-106190","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IRIDEX signs 90-month lease for new HQ in San Jose; annual rent starts at $646K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease of 30,784 sq ft at 5215 Hellyer Ave, San Jose, CA; term 90 months starting July 1, 2026.","Annual base rent: Year 1 $646,464 ($53,872/month) escalating ~3% annually.","Six-month rent abatement following commencement; tenant responsible for operating expenses, taxes, utilities.","Option to extend term for additional 60 months at greater of prior rent or market rent.","Security deposit of $132,500; lease is triple net."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100161,"accession_number":"0001193125-26-009912","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q4 2025 revenue up 15-17% YoY to ~$14.7M; positive cash flow in quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue expected $14.6-14.8M vs $12.7M prior year, +15-17% YoY.","Full-year 2025 revenue expected $52.5-52.7M vs $48.7M in 2024, +8% YoY.","Achieved positive cash flow in Q4 and expects positive adjusted EBITDA for full-year 2025.","Sold 15,800 Cyclo G6 probes in Q4 (up 19% YoY); 44 systems sold vs 47 prior year.","CEO cites cost reductions, gross margin expansion, and improved commercial efficiency as drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":52675000.0,"consensus_period":"2026-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116499,"accession_number":"0001193125-25-315298","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"IRIDEX to present at Sidoti conference Dec 11, 2025; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company participating in Sidoti Year-End Virtual Investor Conference on December 11, 2025.","Presentation materials furnished as Exhibit 99.1 but no specific financial or operational data provided.","No new guidance, results, or material events reported in the filing or exhibits.","Webcast available on IRIDEX investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116498,"accession_number":"0001193125-25-277598","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q3 revenue $12.5M (+8% YoY); expects positive adjusted EBITDA in FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.5M (+8% YoY); Cyclo G6 revenue $3.5M (+13%); Retina revenue $6.7M (+4%).","Gross margin 32.1% down 520 bps due to one-time $0.8M inventory write-down; operating expenses down 12%.","Net loss $1.6M ($0.09 per share) vs $1.9M ($0.12) prior year; adjusted EBITDA loss improved to $0.1M from $1.4M.","Cash $5.6M, down $1.2M in quarter; guidance: cash flow breakeven in Q4 and positive adjusted EBITDA for full year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":37951000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132949,"accession_number":"0001193125-25-199190","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IRIDEX regains Nasdaq minimum stockholders' equity compliance; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified IRIDEX on Aug 27, 2025, that it now meets the $2.5M stockholders' equity requirement under Listing Rule 5550(b)(1).","Non-compliance had been triggered by the Q1 2025 10-Q filed May 13, 2025; resolved after Q2 2025 10-Q filed Aug 12, 2025.","The delisting matter is formally closed; IRIX continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132948,"accession_number":"0000950170-25-107345","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q2 revenue $13.6M (+7% YoY), net loss narrows to $1.0M; third straight positive adjusted EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.6M, up 7% YoY and 14% sequential; retina product revenue $8.0M (+10% YoY).","Cyclo G6 revenue $3.3M (flat YoY); sold 13,100 probes vs 15,100, and 35 systems vs 28.","Gross margin 34.5% vs 40.7% a year ago due to higher costs and product mix.","Operating expenses down 28% YoY to $5.6M; net loss $1.0M ($0.06/sh) vs $2.7M ($0.16/sh).","Non-GAAP adjusted EBITDA positive $21k, vs loss of $1.7M; cash $6.8M, down $0.4M in quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":25467000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149503,"accession_number":"0000950170-25-086292","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"IRIDEX stockholders approve doubling authorized shares to 63.5M and 1M share increase in equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 30M to 63.5M shares; Restated Charter effective June 11, 2025.","2008 Equity Incentive Plan amended: reserve increased by 1M shares (total 6.85M), term extended to June 11, 2035.","Stockholders approved removal of 19.99% issuance limit for conversion of Series B Preferred and $4M note held by Novel.","All director nominees elected; BPM LLP ratified as auditor for FY2026; say-on-pay approved with one-year frequency.","Series B Preferred (600k shares) voted in favor of all proposals; common vote percentages ranged 80-92% for director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149502,"accession_number":"0000950170-25-076352","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IRIDEX amends Investor Rights Agreement; board unanimous consent required for major asset sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 20, 2025, IRIDEX amended its Investor Rights Agreement with Novel Inspiration International Co.","Amendment requires unanimous board consent for disposal of a substantial portion of assets (less than substantially all).","Exception for dispositions to a wholly-owned subsidiary.","Original agreement dated March 19, 2025; this adds a governance restriction on asset dispositions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149501,"accession_number":"0001174947-25-000809","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"IRIDEX receives Nasdaq delisting notice; equity only $852K vs $2.5M minimum; seeks shareholder vote","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was ~$852,000 as of March 29, 2025, below Nasdaq's $2.5M minimum.","Company to seek shareholder approval at June 11, 2025 annual meeting to reclassify Series B Preferred Stock as permanent equity.","If approved, $6M Series B sale would reclassify, potentially bringing equity above minimum.","Must submit compliance plan to Nasdaq by June 30, 2025; may receive up to 180-day cure period if plan accepted.","No immediate impact on Nasdaq listing or business operations, but delisting risk remains if plan fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149500,"accession_number":"0000950170-25-070385","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q1 revenue $11.9M, positive adj EBITDA $0.4M after $10M strategic investment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $11.9M (flat YoY); Cyclo G6 glaucoma revenue up 8% to $3.2M; Retina revenue down 3% to $6.6M.","Adjusted EBITDA improved to $0.4M from ($2.5M) YoY; net loss narrowed to $1.7M ($0.10/share) from $3.5M ($0.21).","Operating expenses cut 32% to $5.3M; gross margin expanded to 42.5% from 37.9% on favorable product mix.","Received $10M strategic investment from Novel Inspiration; Lind note payable settled, reducing debt.","2025 outlook: cash flow breakeven and positive adjusted EBITDA on 2024-level revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":11896000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149499,"accession_number":"0000950170-25-053714","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q1 preliminary revenue flat at ~$11.8-12.0M; probe volumes up 4.5% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue expected $11.8M-$12.0M vs $11.8M in Q1 2024.","Cyclo G6 probe sales rose to ~13,900 units (+4.5% YoY); laser systems 24 vs 22.","Cash and equivalents $7.2M as of March 29, 2025.","CEO cites business stabilization and improved financials after Novel strategic investment; aims for breakeven at historical revenue levels; investor call April 16."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":11896000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149498,"accession_number":"0001193125-25-075760","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Kenneth E. Ludlum resigns from IRIDEX Board effective April 7, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth E. Ludlum resigned from IRIDEX Board and all committees effective April 7, 2025.","Resignation fulfills provisions of the Investor Rights Agreement with Novel Inspiration International Co., Ltd.","Mr. Ludlum's departure is not due to any disagreement with the Company.","Board expressed appreciation for Ludlum's years of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149497,"accession_number":"0001193125-25-072447","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IRIDEX director Robert E. Grove resigns effective April 2, 2025 per Novel transaction agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert E. Grove resigned from the Board and all committees effective April 2, 2025.","Resignation is not due to any disagreement with the Company on operations, policies, or practices.","Resignation fulfills provisions of the Investor Rights Agreement with Novel Inspiration International Co., Ltd.","Board size remains at five directors as per the Rights Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168575,"accession_number":"0000950170-25-046076","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex posts Q4 2024 revenue $12.7M, achieves positive adjusted EBITDA; net loss narrows to $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $12.7M vs $12.5M YoY; adjusted EBITDA positive $0.4M vs ($2.0M) loss prior year.","Net loss improved to $0.8M ($0.05/share) from $3.0M ($0.18/share); operating expenses down 24% to $6.1M.","Cyclo G6 product family revenue $3.3M (+9% YoY); retina product revenue $7.3M (-3%).","Cash $2.4M at year-end; subsequent $10M strategic investment from Novel Innovations at $2.00/share.","Guidance: expects cash flow breakeven and positive adjusted EBITDA in 2025 on FY revenue consistent with 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168574,"accession_number":"0000950170-25-042190","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["1.01","5.03","1.02","2.03","3.02","5.02","8.01","9.01"],"status":"ready","headline":"IRIDEX raises $10M via preferred stock and convertible note; repays Lind debt; new CFO and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 600K Series B Preferred at $10/sh (convertible into 3M common) and $4M 12% convertible note to Novel Inspiration.","Repaid Lind Global $3.33M, terminating Lind convertible note; remaining proceeds for general corporate purposes.","Board appointed William Moore and Nick Chen as directors (Novel nominees) effective upon closing.","Romeo Dizon appointed CFO (replacing Fuad Ahmad); $300K base salary and change-in-control severance.","Novel receives registration rights, two board seats, and veto power over specified corporate actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168573,"accession_number":"0000950170-25-005194","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q4 revenue $12.6-12.7M, flat YoY; FY 2024 revenue $48.6-48.7M, down 6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue expected $12.6-12.7M vs $12.5M in prior year; sold 47 Cyclo G6 systems (vs 35).","Full year revenue $48.6-48.7M; down from $51.9M in 2023; system sales dropped to 125 from 164.","Strategic review remains ongoing with multiple parties for single or multiple transactions.","Cost restructuring implemented; Q4 achieved positive EBITDA; focus on profitability in 2025.","Cyclo G6 probe sales flat at 12,700 in Q4; full year 54,800 vs 55,200 in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":48669000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185687,"accession_number":"0000950170-24-130698","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IRIDEX appoints CEO Patrick Mercer to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed effective November 22, 2024, with initial term ending at 2025 annual meeting.","No change to Mercer's existing compensatory arrangements; no additional compensation for board service.","Mercer is currently President, CEO, and COO; no arrangements or understandings with others for appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185683,"accession_number":"0000950170-24-130699","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K/A","filed_at":"2024-11-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IRIDEX corrects CEO Bruce's resignation date; details severance and Mercer's CEO comp","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Bruce terminated as CEO Oct 1, resigned board Nov 22, 2024; no disagreement with company policies.","Separation agreement: $45K lump sum ($20K COBRA, $25K intangibles) plus accelerated vesting of 19,913 RSUs and options for 40,431 shares.","New CEO Patrick Mercer retains $360K base salary, annual target bonus 65% of base, amended change-in-control severance (150% base salary)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185686,"accession_number":"0000950170-24-126507","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"IRIDEX CEO David Bruce terminated; Patrick Mercer takes over as CEO effective Nov 7, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Bruce terminated as CEO Oct 1, 2024, resigned from Board Nov 11, 2024; receives $45K cash and acceleration of 19,913 RSUs and 40,431 options.","Patrick Mercer appointed CEO; retains base salary of $360K, target bonus 65% of base, and new change-in-control severance at 150% of salary.","Kenneth E. Ludlum appointed to Compensation Committee; committee composition updated.","Bruce's separation agreement includes non-disparagement, confidentiality, and release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185685,"accession_number":"0000950170-24-125464","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q3 revenue $11.6M (-10% YoY); net loss $1.9M; expects EBITDA breakeven in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $11.6M, down 10% YoY; retina revenue $6.5M (-18% YoY).","Cyclo G6 glaucoma revenue $3.1M (+3% YoY) with 13,600 probes sold.","Net loss $1.9M ($0.12/sh) vs $1.8M loss ($0.11/sh) in Q3'23; gross margin 37.3% vs 43.7%.","Appointed Patrick Mercer as CEO (effective Oct 1, 2024); strategic review ongoing with multiple parties.","New Medicare LCDs effective Nov 17, 2024 expected to boost glaucoma product adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":35973000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185684,"accession_number":"0000950170-24-112474","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Iridex appoints Patrick Mercer as CEO; strategic review for potential transaction ongoing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Mercer named CEO and President effective Oct 1, 2024; previously COO and President.","David Bruce transitions out; Scott Shuda appointed Executive Chairman.","Board believes leadership change may accelerate strategic review process for a potential transaction.","Company engaged in discussions with multiple entities regarding potential transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202256,"accession_number":"0000950170-24-104222","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IRIDEX files S-3 to register resale of up to ~1.7M shares from $4.2M convertible note","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed registration statement for resale of shares issuable upon conversion of $4.2M senior convertible note to Lind Global.","Conversion price $2.44 per share; full conversion would add ~1.7M shares to outstanding.","No Note Shares currently outstanding; Incentive Shares already issued under Purchase Agreement.","Company believes actual conversions substantially less but provides no assurance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202255,"accession_number":"0000950170-24-093966","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Iridex Q2 revenue flat at $12.6M; net loss $2.7M; raises $3.4M via convertible note","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $12.6M, flat YoY; net loss $2.7M ($0.16 EPS) vs $2.8M loss in prior year.","Cyclo G6 probe sales up 14% sequentially to 15,100 units; Retina revenue $7.3M, +6% YoY.","Cash $4.1M at quarter end; net cash burn $1.3M in Q2.","Closed $3.4M convertible note with Lind Partners on Aug 7; strengthens liquidity.","Strategic review ongoing; CEO expects transaction within fiscal year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":24392000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202254,"accession_number":"0000950170-24-090371","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Iridex secures $3.5M convertible note from Lind; potential $1.5M add-on","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds ~$3.5M from $4.2M principal senior convertible note to Lind; $1.5M additional note available.","Conversion price $2.44/share (floor $0.39); 24-month term, monthly repayments start after 120 days.","Company may pay in cash (+4% premium) or shares at 90% of avg of 5 lowest VWAPs over 20 trading days.","126,968 incentive shares issued at close; additional shares if initial note not repaid within 180 days.","Company to file resale registration within 30 days and seek stockholder approval for share issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202253,"accession_number":"0001193125-24-175053","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"IRIDEX receives Nasdaq notice for MVLS below $50M; plans transfer to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On June 27, 2024, Nasdaq notified IRIX that its market value of listed securities was below $50M for 30 consecutive business days.","Company intends to transfer listing from Nasdaq Global Market to Nasdaq Capital Market to regain compliance.","Notice has no immediate effect on trading; shares continue on Nasdaq under symbol IRIX.","Application for transfer must meet Capital Market requirements; company expects acceptance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218341,"accession_number":"0000950170-24-075755","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"IRIDEX holds annual meeting; elects all six director nominees, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders re-elected David Bruce, Robert Grove, Beverly Huss, Kenneth Ludlum, Scott Shuda as directors.","Ratified BPM LLP as independent auditor for FY2024 with 10,213,704 votes for.","Advisory 'say-on-pay' passed with 4,635,945 for (approx 73% of votes cast excluding broker non-votes).","Board modified Audit Committee: Kenneth Ludlum chair, Beverly Huss and Robert Grove members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218340,"accession_number":"0000950170-24-064595","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IRIDEX appoints Patrick Mercer as President; CEO focuses on strategic alternatives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Mercer appointed President, effective May 22, 2024; remains COO with expanded operational focus.","CEO David Bruce will concentrate on pursuing strategic alternatives for the company.","Mercer's base salary increased to $360,000; granted 120,000 RSUs vesting one-third annually over three years.","RSU award subject to continued employment and IRIDEX's 2008 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218339,"accession_number":"0000950170-24-059624","cik":1006045,"company_name":"IRIDEX CORP","ticker":"IRIX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iridex Q1 revenue down 14% to $11.8M; net loss widens; strategic review ongoing after deal collapse","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $11.8M vs $13.7M YoY; net loss $3.5M ($0.21/share) vs $2.1M ($0.13/share).","Cyclo G6 revenue $3.0M (down 19% YoY); system sales fell to 22 units from 61.","Retina product revenue $6.8M, down 6% YoY; gross margin contracted to 37.9% from 43.3%.","Cash $5.4M as of March 30, 2024; used $1.6M in the quarter.","First expected asset sale terminated; strategic review continues with multiple parties on product lines or whole company."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":11761000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17928711.836538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}